story of the week
ASCO 2019: SOPHIA Trial Shows Promise for Margetuximab in HER2-Positive Breast Cancer
This is the first trial to use CD16A genotype as a predictor of response
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: